These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Kaseda K; Asakura K; Kazama A; Ozawa Y World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499 [TBL] [Abstract][Full Text] [Related]
46. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Benyounes H; Smith FW; Campbell C; Evans NT; Norton MY; Mikecz P; Heys SD; Bruce D; Eremin O; Sharp PF Nucl Med Commun; 1995 Jul; 16(7):575-80. PubMed ID: 7478396 [TBL] [Abstract][Full Text] [Related]
47. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730 [TBL] [Abstract][Full Text] [Related]
48. 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma. Gontier E; Wartski M; Guinebretiere JM; Alberini JL AJR Am J Roentgenol; 2006 Sep; 187(3):W285-9. PubMed ID: 16928906 [No Abstract] [Full Text] [Related]
49. An 18-year delay in the clinical presentation of bronchial carcinoid. Leuzzi G; Forcella D; Melis E; Visca P; Facciolo F Rev Esp Med Nucl Imagen Mol; 2015; 34(5):327-8. PubMed ID: 25630601 [No Abstract] [Full Text] [Related]
50. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702 [TBL] [Abstract][Full Text] [Related]
51. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases. Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722 [TBL] [Abstract][Full Text] [Related]
52. FDG PET/CT imaging in prostate adenocarcinoma presenting as isolated brain metastases of unknown origin. Erhamamcı S; Reyhan M; Alkan O Rev Esp Med Nucl Imagen Mol; 2015; 34(2):146-7. PubMed ID: 25052407 [No Abstract] [Full Text] [Related]
53. Incidental diagnosis of endometrial carcinoma in a patient with breast cancer by FDG PET/CT. Chang CC; Chen YW; Hou MF Clin Nucl Med; 2007 Mar; 32(3):205-7. PubMed ID: 17314597 [No Abstract] [Full Text] [Related]
54. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. London K; Lin M Ann Surg Oncol; 2011 Jan; 18(1):291. PubMed ID: 20505997 [No Abstract] [Full Text] [Related]
55. Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy. Shimizu N; Masuda H; Yamanaka H; Oriuchi N; Inoue T; Endo K J Urol; 1999 Feb; 161(2):608-9. PubMed ID: 9915462 [No Abstract] [Full Text] [Related]
56. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT]. Moragas M; Soler M; Riera E; García JR Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280 [TBL] [Abstract][Full Text] [Related]
57. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Nakata B; Chung YS; Nishimura S; Nishihara T; Sakurai Y; Sawada T; Okamura T; Kawabe J; Ochi H; Sowa M Cancer; 1997 Feb; 79(4):695-9. PubMed ID: 9024707 [TBL] [Abstract][Full Text] [Related]
58. Detection of gall bladder cancer metastases in rare sites by PET scan. Shukla PJ; Barreto SG; Shrikhande SV; Mohandas KM; Purandare N; Rangarajan V Indian J Gastroenterol; 2007; 26(6):303-4. PubMed ID: 18431025 [No Abstract] [Full Text] [Related]